Core Insights - OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines targeting cancers that are underserved by existing therapies [2] - The company is utilizing a structure-based drug design platform to create a pipeline of tumor-agnostic candidates aimed at achieving optimal efficacy and tolerability [2] - OnKure's lead program is OKI-219, a selective PI3Kα inhibitor, with the goal of becoming a leader in targeting oncogenic or pathologically activated PI3Kα [2] Upcoming Events - The CEO, Nichoals Saccomano, will present at the Guggenheim Healthcare Innovation Conference on November 10, 2025, at 4:00 p.m. ET [4] - A corporate presentation will take place at the Stifel Healthcare Conference on November 12, 2025, at 4:00 p.m. ET [4] - A fireside chat is scheduled for the Evercore Healthcare Conference on December 3, 2025, at 12:30 p.m. ET [4]
OnKure Therapeutics to Participate in Upcoming Investor Conferences